Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current status of HER2 testing.

Angelo Di Leo1, Mitch Dowsett, Bruce Horten

  • 1Translationsl Research Unit, Department of Chemotherapy, Institut Jules Bordet, Rue Heger Bordet 1, B-1000 Brussels, Belgium. angelo.dileo@bordet.be

Oncology
|November 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selecting patients with HER2-low breast cancer: Getting out of the tangle.

European journal of cancer (Oxford, England : 1990)·2022
Same author

Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.

Virchows Archiv : an international journal of pathology·2022
Same author

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.

Virchows Archiv : an international journal of pathology·2022
Same author

Circulating proteins as predictive and prognostic biomarkers in breast cancer.

Clinical proteomics·2022
Same author

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

BMC cancer·2022
Same author

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022

Accurate HER2 testing is crucial for breast cancer prognosis and Herceptin eligibility. This review covers immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) methods, discussing optimal testing strategies for clinicians and pathologists.

Area of Science:

  • Oncology
  • Pathology
  • Molecular Diagnostics

Background:

  • HER2 gene amplification and overexpression correlate with poorer prognosis in tumors.
  • Positive HER2 status is essential for eligibility for Herceptin (trastuzumab) therapy in metastatic breast cancer.
  • Accurate HER2 assessment is critical for treatment decisions and patient outcomes.

Purpose of the Study:

  • To review current guidelines and clinical opinions on HER2 testing in breast cancer.
  • To compare the advantages and disadvantages of immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) for HER2 assessment.
  • To discuss optimal timing and location for HER2 testing.

Main Methods:

  • Review of recent experiences, guidelines, and expert opinions on HER2 testing.

Related Experiment Videos

  • Comparison of immunohistochemistry (IHC) for protein overexpression and fluorescence in-situ hybridization (FISH) for gene amplification.
  • Discussion of logistical aspects: when to test and where to test.

    • Main Results:

    • IHC and FISH are the predominant methods for routine clinical HER2 testing.
    • Debate exists regarding the optimal approach to HER2 testing, including timing and methodology.
    • Considerations include the relative merits of IHC versus FISH and centralized versus local laboratory testing.

    Conclusions:

    • Standardized and reliable HER2 testing is paramount for guiding breast cancer treatment, particularly for Herceptin therapy.
    • Pathologists and oncologists must consider the nuances of IHC and FISH testing, including when and where testing is performed.
    • Further consensus and guideline refinement are needed to optimize HER2 assessment in clinical practice.